Abcam, ab317453, Anti-VAChT antibody [EPR29154-71] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal VACHT antibody. Carrier free. Suitable for mIHC, IHC-P, Flow Cyt (Intra), WB, IHC-Fr, ICC/IF, IP and reacts with Rat, Mouse samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR29154-71,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Mouse, Rat,
Applications:Flow Cyt (Intra), IHC-P, IP, mIHC, ICC/IF, IHC-Fr, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab317453 is the carrirer-free version of
ab317452
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The vesicular acetylcholine transporter often referred to as VAChT is responsible for packaging acetylcholine into vesicles in cholinergic neurons. This process is important for synaptic transmission in the nervous system. VAChT functions by using a proton gradient to transport acetylcholine against its concentration gradient into synaptic vesicles. VAChT has a molecular mass of approximately 55 kDa. It is widely expressed in cholinergic neurons throughout the central and peripheral nervous systems particularly in regions such as the cortex hippocampus and neuromuscular junctions.
Biological function summary
The function of VAChT plays an important role in the cholinergic system by facilitating neurotransmitter storage essential for neural communication. As part of the vesicular neurotransmitter transporter family VAChT collectively works with other proteins within this complex system to regulate acetylcholine availability and release. The stored acetylcholine within vesicles is released into the synaptic cleft in response to neuronal signals which promotes synapse firing and communication between neurons.
Pathways
Acetylcholine packaging and release managed by VAChT is integral to the cholinergic signaling pathway. This pathway is fundamental to ensuring proper function of learning memory and muscle control processes. VAChT works closely with the protein choline acetyltransferase (ChAT) which synthesizes acetylcholine from choline and acetyl-CoA. These proteins ensure a seamless conversion and transport loop within cholinergic neurons to maintain efficient neural signaling.
VAChT has been linked to conditions that involve impaired cholinergic function such as Alzheimer's disease and myasthenia gravis. In Alzheimer's disease disruptions in the cholinergic system often marked by reduced VAChT expression contribute to cognitive decline. VAChT variations can also impact acetylcholine availability in myasthenia gravis a disorder characterized by muscle weakness. In both cases the relationship between VAChT and ChAT is important as ChAT levels often change in parallel affecting overall cholinergic signaling and response.